Guidelines recommend upper and lower gastrointestinal endoscopic evaluation for patients without a clear physiological explanation for iron deficiency anemia (IDA). However, the consequences of watchful waiting in older patients with unexplained IDA in general practice are unknown. The aim of this study wa...
Suzetrigine (brand name Journavx) is a recently approved, first-in-class, oral, non-opioid analgesic indicated for the treatment of moderate to severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in 2025, it represents the first novel mechanistic class of oral analgesic in ...